Becton Dickinson (BDX) has recently resolved the major portion of its outstanding hernia litigation, costing them more than a billion dollars in settlements. The
investment activity from major banks like the Czech National Bank and Creative Planning has increased, demonstrating confidence despite the litigation. The stability of the company is further confirmed by effective
debt management and strong value in
stock. Experts also have a positive outlook on the company, with Citigroup upgrading their stock rating and setting a new price target. BDX is viewed as a robust
value, growth, and momentum stock, ideal for long-term investment. Their
quarterly earnings have beaten estimates, they've increased their
dividend payout, and completed the notable acquisition of the
Critical Care section from Edwards Lifesciences. A new research tool aiding the study of cells involved in cancer and infectious diseases development has been launched and Michael Feld has been appointed as the President of the Life Sciences segment.
Short interest in BDX went up by 33.8% in August, suggesting the stock may be undervalued. With fruitful collaboration with
Quest Diagnostics and
Hamilton underway, FDA clearance for a new product, and a successful adaptation to challenges, BDX has dynamically proven its skill in navigating the market.
Becton Dickinson and BDX News Analytics from Thu, 07 Dec 2023 08:00:00 GMT to Sat, 05 Oct 2024 14:46:48 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor 3
